Revenue Breakdown
Composition ()
No data
Revenue Streams
Profitability & Margins
Evaluating the bottom line, Skye Bioscience Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -94.31%, provide a clear picture of how effectively SKYE converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, SKYE competes directly with industry leaders such as BRNS and DARE. With a market capitalization of $24.40M, it holds a significant position in the sector. When comparing efficiency, SKYE's gross margin of N/A stands against BRNS's N/A and DARE's 100.00%. Such benchmarking helps identify whether Skye Bioscience Inc is trading at a premium or discount relative to its financial performance.
